

Get the latest on the Cleocin (Clindamycin) shortage in 2026. Learn why it's hard to find, current costs, and how to get your prescription filled.
If your pharmacist has told you that Cleocin — or its generic, Clindamycin — is unavailable or on back order, you're experiencing one of the longest-running drug shortages in the United States. The Clindamycin injectable shortage has been ongoing since at least 2015, and as of 2026, certain forms remain difficult to find.
Here's what you need to know about the current state of the shortage, why it's happening, and what you can do about it.
The short answer: it depends on the formulation.
Clindamycin Phosphate Injection: Yes, still in shortage. This has been on the ASHP (American Society of Health-System Pharmacists) drug shortage list continuously since June 2015. Pfizer's brand-name Cleocin Phosphate injection (150 mg/mL, 4 mL vials) has been on back order. Sagent Pharmaceuticals' 60 mL vials are also on back order with no estimated release date.
Oral Capsules (Clindamycin HCl): Generally available from multiple generic manufacturers, though individual pharmacies may experience temporary stock-outs due to distributor allocation limits or regional demand spikes.
Topical and Vaginal Forms: Topical gels, lotions, foams, and vaginal preparations are generally in better supply, with generic options from companies like Glenmark, Taro, and others.
Several factors contribute to the ongoing difficulty:
Injectable antibiotics require specialized sterile manufacturing facilities. Only a small number of companies produce Clindamycin injection, and when any one of them faces production issues, the entire market feels the impact. This is the primary driver of the decade-long injectable shortage.
The pharmaceutical supply chain has become highly consolidated. Fewer manufacturers making each drug means less resilience when disruptions occur. For a generic antibiotic like Clindamycin, profit margins are thin, which discourages new manufacturers from entering the market.
Clindamycin is one of the most frequently prescribed antibiotics in the U.S. It's the go-to choice for patients allergic to penicillin, a mainstay for dental infection prophylaxis, and commonly used for MRSA skin infections. This high baseline demand means even small supply disruptions create noticeable shortages.
Even when Clindamycin is being manufactured, distribution can be uneven. Pharmacies in some regions may have adequate stock while others are completely out. Large chain pharmacies may receive priority allocations, leaving smaller pharmacies underserved.
Cost is another challenge for patients, especially those without insurance:
The good news is that generic Clindamycin is on Tier 1 of most insurance formularies, meaning copays are typically low ($0-$15). Discount cards from GoodRx, SingleCare, and Optum Perks can also bring cash prices down significantly. For a comprehensive savings guide, read how to save money on Cleocin.
While no fundamentally new Clindamycin products have launched, the generic landscape continues to evolve:
Here are your best strategies for locating Clindamycin:
For a detailed playbook, read our guide on how to find Cleocin in stock near you.
The Cleocin shortage is frustrating, but it's manageable with the right information. The injectable form remains in a serious, long-running shortage, while oral and topical forms are generally available with some effort.
Stay proactive: use Medfinder to search pharmacy stock, explore discount cards to manage costs, and talk to your doctor about alternatives if you truly can't find Clindamycin. Understanding your options is the best defense against a drug shortage.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.